Form 4 for EW Edwards Lifesciences
Accepted 2023-09-29 00:00:00 ET · period of report 2023-09-29 · accession 0001225208-23-009087 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-29 | 2023-09-29 | EW | Ullem Scott B. | CFO, CVP | S - Sale+OE | $69.54 | -7,255 | 19.2K | -27% | -$504.5K |
| D | 2023-09-29 | 2023-09-29 | EW | Ullem Scott B. | CFO, CVP | M - OptEx | $36.75 | +7,255 | 26.5K | +38% | +$266.6K |
| D | 2023-09-29 | 2023-09-29 | EW | Ullem Scott B. | CFO, CVP | M - OptEx | $0.00 | -7,255 | 50.8K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-29 | S | D | 7,255 | $69.54 | 19,248 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $69.21 to $70.08. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2023-09-29 | M | A | 7,255 | $36.75 | 26,503 | D | — | — | |
| 3 | Derivative | Employee Stock Option (Right to Acquire) | 2023-09-29 | M | D | 7,255 | $0.00 | 50,780 | D | $36.75 · 2018-05-11 to 2024-05-10 | 7,255 Common Stock |